leisure time -WSS

leisure time

author：focus 2025-09-30 00:36:02 - browse：4958

Adam's take main illustration — Molly Ferguson/STAT

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Medicare to cover more brain scans related to Alzheimer’s drugs

focus

WSS

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Rare Northern Lights show in US this week: Where and how to see it

Humana CEO Bruce Broussard to step down in 2024

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

European regulators consider appeal over Amylyx ALS drug

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

Wikipedia

leisure time

leisure time

Sports medicine is finally prioritizing gender equality

What the Wegovy shortage looks like for doctors — and for patients

Medical records are filled with copy

A revolution in caring for preterm infants

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Female surgeons have lower rates of long

In age of alternative facts, a scholarly course on calling out crap

Massive project maps cells in human brain in unprecedented detail

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD podcast: Merger Mondays, Ozempic panic

leisure time

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Cancer cells are shown to suck energy source from immune cells

Wellcome Trust names Røttingen as its new CEO

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

European regulators recommend Amylyx's ALS drug be rejected

Peter Marks talks Operation Warp Speed for Rare Diseases

focus

knowledge

Wikipedia

entertainment